Microcap Ledger PMV Pharmaceuticals, Inc. $PMVP
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Princeton, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 53,458,058 [10-Q 2026-08-14]
What the company doesAI summary of filing
PMV Pharmaceuticals is a clinical-stage biopharmaceutical company developing product candidates targeting p53 mutations. The company is pre-revenue and does not currently generate revenues from product sales. PMV is advancing clinical trials for its product candidates, including rezatapopt as its lead candidate, and plans to seek regulatory approvals and commercialize these candidates if approved. The company relies on existing cash, cash equivalents, and marketable securities to fund operations and development activities. [10-K 2026-03-06]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$36.12M | −$34.26M | $12.47M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$77.74M | −$73.58M | $37.98M | [DEF 14A 2026-04-22] |
| FY ended Dec 2024 | — | −$58.90M | −$51.28M | $40.88M | [DEF 14A 2026-04-22] |
- Quarterly cash burn
- −$17.13M
- Cash runway Estimate
- ~2.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 51,747,130 | [10-Q 2024-11-07] |
| 2025-03-03 | 51,933,604 | [10-K 2025-03-03] |
| 2025-05-09 | 51,952,680 | [10-Q 2025-05-09] |
| 2025-08-07 | 52,990,864 | [10-Q 2025-08-07] |
| 2025-11-12 | 53,211,507 | [10-Q 2025-11-12] |
| 2026-03-03 | 53,329,392 | [10-K 2026-03-06] |
| 2026-05-12 | 53,331,766 | [10-Q 2026-05-12] |
| 2026-08-14 | 53,458,058 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2024-11-20; declared effective 2024-11-27 [S-3 2024-11-20]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-05 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-09-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-02 | 8-K | Material agreement entered; Other events |
| 2026-09-02 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-31 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-31 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-31 | 8-K | Other events |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 8-K | Results of operations |
| 2026-07-28 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-10 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-05 | 8-K | Shareholder vote results |
Alerts for $PMVP
Email me when PMV Pharmaceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.